Table 1. . Descriptive characteristics of patients.

Characteristics	All patients (n = 215)
Age (years) Median (range)	62 (23–91)
Gender, n (%) – Male – Female	99 (46.0) 116 (54.0)
Race, n (%) – Whites – Blacks – Hispanics – Others	188 (87.5) 17 (7.9) 5 (2.3) 5 (2.3)
Cancer type, n (%) – Lung – Melanoma – Urothelial – Renal – Head and neck – Gynecologic – Other	59 (27.4) 40 (18.6) 15 (7.0) 14 (6.5) 24 (11.2) 33 (15.3) 30 (14.0)
ECOG PS, n (%) – 0 – 1 – 2/3	63 (29.3) 115 (53.5) 37 (17.2)
Checkpoint inhibitor, n (%) – Nivolumab – Pembrolizumab – Ipilimumab/nivolumab – Atezolizumab – Other	68 (31.6) 81 (37.7) 20 (9.3) 14 (6.5) 32 (14.9)
Line of therapy, n (%) – 1 – 2 – ≥3	39 (18.1) 94 (43.7) 82 (38.1)

ECOG PS: Eastern Cooperative Oncology Group Performance Status.